0001193125-22-024600.txt : 20220201 0001193125-22-024600.hdr.sgml : 20220201 20220201161400 ACCESSION NUMBER: 0001193125-22-024600 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220126 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220201 DATE AS OF CHANGE: 20220201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kura Oncology, Inc. CENTRAL INDEX KEY: 0001422143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37620 FILM NUMBER: 22579088 BUSINESS ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 500-8800 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP III DATE OF NAME CHANGE: 20071227 8-K 1 d661588d8k.htm 8-K 8-K
false 0001422143 0001422143 2022-01-26 2022-01-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 26, 2022

 

 

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37620   61-1547851
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

12730 High Bluff Drive, Suite 400, San Diego, CA   92130
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   KURA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.

In connection with Dr. Grasso’s resignation, the Company and Dr. Grasso intend to enter into a Separation Agreement (the “Grasso Agreement”) pursuant to which, among other things, following the Separation Date, Dr. Grasso will provide advisory services to the Company for a period of up to three months (the “Advisory Period”). As consideration for Dr. Grasso’s advisory services, Dr. Grasso’s outstanding equity awards will continue to vest during the Advisory Period.

(c)

On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.

Mr. Doyle, age 51, has served as the Company’s Vice President, Finance since June 2021. Prior to joining the Company, Mr. Doyle served as Vice President of Finance for Zogenix Inc., a public biopharmaceutical company, from 2013 until June 2021. Prior to that, Mr. Doyle served as Controller for Peregrine Pharmaceuticals,    Inc. (now Avid Bioservices, Inc.), a public oncology development and biomanufacturing company, as Director of Revenue and Cost Accounting for ISTA Pharmaceuticals, Inc., a public pharmaceutical company, and as the Director of Internal Audit and R&D Finance at Valeant Pharmaceuticals International, a public pharmaceutical company. Mr. Doyle is a certified public accountant and received his M.B.A. from California State University San Marcos and his B.S. in finance from San Diego State University.

In connection with Mr. Doyle’s employment changes mentioned above, the Company entered into an amended & restated employment agreement with Mr. Doyle on January 31, 2022 (the “Doyle Agreement”). Pursuant to the Doyle Agreement, Mr. Doyle is (i) entitled to an annual base salary of $333,500, (ii) eligible to receive an annual discretionary bonus of up to 35% of his then current base salary, (iii) entitled to receive an additional option to purchase 39,281 shares of the Company’s common stock and (iv) entitled to receive an additional restricted stock unit award covering 8,390 shares of the Company’s common stock. The shares subject to the option shall vest in a series of 48 successive equal monthly installments from February 7, 2022. The shares subject to the restricted stock unit award shall vest in a series of four successive equal annual installments from January 26, 2022. In each case, vesting of the equity awards is subject to Mr. Doyle’s continuous service with the Company.

Pursuant to the Doyle Agreement, subject to providing a release of claims against the Company, Mr. Doyle is entitled to, (i) in the event that we terminate his employment without cause or he resigns for good reason more than 59 days prior to or 12 months after the closing of a corporate transaction, (a) a cash lump-sum payment in an amount equal to nine months of Mr. Doyle’s then annual base salary and (b) payment of COBRA group health insurance premiums for up to nine months, and (ii) in the event that we terminate his employment without cause or he resigns for good reason within 59 days before, on or within 12 months after the closing of a corporate transaction, (i) a cash lump-sum payment in an amount equal to nine months of Mr. Doyle’s then annual base salary, (ii) a cash lump-sum payment in an amount equal to Mr. Doyle’s full target bonus amount for services to be performed during the year in which the corporate transaction occurs and (iii) payment of COBRA group health insurance premiums for up to nine months. Mr. Doyle is also eligible for standard company benefits and to participate in employee benefit plans and programs.

Ms. Doyle’s employment is at-will and may be terminated at any time by either Mr. Doyle or by us with or without cause and without notice.

Mr. Doyle has no family relationships with any of the Company’s directors or executive officers, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. In addition, there are no arrangements or understandings between Mr. Doyle and any other person pursuant to which he was selected to his roles with the Company.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    KURA ONCOLOGY, INC.
Date: February 1, 2022     By:  

/s/ Teresa Bair

      Teresa Bair
      Chief Legal Officer
EX-101.SCH 2 kura-20220126.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 kura-20220126_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 kura-20220126_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Jan. 26, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001422143
Document Type 8-K
Document Period End Date Jan. 26, 2022
Entity Registrant Name KURA ONCOLOGY, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37620
Entity Tax Identification Number 61-1547851
Entity Address, Address Line One 12730 High Bluff Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 500-8800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol KURA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d661588d8k_htm.xml IDEA: XBRL DOCUMENT 0001422143 2022-01-26 2022-01-26 false 0001422143 8-K 2022-01-26 KURA ONCOLOGY, INC. DE 001-37620 61-1547851 12730 High Bluff Drive Suite 400 San Diego CA 92130 (858) 500-8800 false false false false Common Stock, par value $0.0001 per share KURA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d661588d8k.htm kura-20220126.xsd kura-20220126_lab.xml kura-20220126_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d661588d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d661588d8k.htm" ] }, "labelLink": { "local": [ "kura-20220126_lab.xml" ] }, "presentationLink": { "local": [ "kura-20220126_pre.xml" ] }, "schema": { "local": [ "kura-20220126.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kura", "nsuri": "http://www.kuraoncology.com/20220126", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d661588d8k.htm", "contextRef": "duration_2022-01-26_to_2022-01-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d661588d8k.htm", "contextRef": "duration_2022-01-26_to_2022-01-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.kuraoncology.com//20220126/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001193125-22-024600-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-024600-xbrl.zip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end